Related Experiment Videos
Intrahepatic cholangiocarcinoma in Hong Kong
1Department of Surgery, University of Hong Kong Medical Center, Queen Mary Hospital, Pokfulam Road, Hong Kong, China.
Insights
Hepatic resection offers the best survival for resectable intrahepatic cholangiocarcinoma, with a median survival of 16.4 months. However, high morbidity and mortality rates highlight the need for careful patient selection.
Area of Science:
- Hepatobiliary Surgery
- Surgical Oncology
- Gastroenterology
Background:
- Intrahepatic cholangiocarcinoma (ICC) is a rare and aggressive biliary tract cancer.
- Treatment options for ICC historically included conservative management, palliative surgery, and hepatic resection.
- Outcomes for ICC patients vary significantly based on treatment modality.
Purpose of the Study:
- To evaluate the efficacy and outcomes of hepatic resection for intrahepatic cholangiocarcinoma.
- To compare survival rates between hepatic resection and other management strategies.
- To identify prognostic factors influencing survival after hepatic resection for ICC.
Main Methods:
- Retrospective analysis of 111 patients with intrahepatic cholangiocarcinoma managed between 1966 and 1998.
- Review of clinical records and survival data for patients undergoing conservative management, palliative operations, or hepatic resection.
- Survival analysis using Kaplan-Meier methods and log-rank tests.
Main Results:
- Median survival was 2.5 months for conservative management and 3.3 months for palliative operations.
- Hepatic resection in 48 patients resulted in a median survival of 16.4 months (1-, 3-, 5-year survival: 60.3%, 29.4%, 22.0%).
- Operative morbidity and mortality rates for hepatic resection were 41.7% and 16.7%, respectively.
- Lymphatic permeation and hilar nodal metastases were significantly associated with poor survival (P=0.007 and P=0.009).
Conclusions:
- Hepatic resection is the treatment of choice for resectable intrahepatic cholangiocarcinoma, offering improved survival.
- Despite improved survival, hepatic resection is associated with significant morbidity and mortality.
- Prognostic factors like lymphatic permeation and nodal status are critical for predicting outcomes in ICC patients undergoing resection.
Abstract:
We retrospectively analyzed the results of hepatic resection for patients with intrahepatic cholangiocarcinoma managed between December 1966 and January 1998 at the University of Hong Kong Medical Center, Queen Mary Hospital. There were 61 men and 40 women (mean age, 61.8 years). The clinical records of these patients were reviewed. A survival analysis was performed on the group of patients who had undergone hepatic resection. Twenty-one patients were treated conservatively. Non-resective (palliative) operations were performed in 32 patients. The median survivals after conservative management and palliative operation were 2.5 and 3.3 months, respectively. The remaining 48 patients underwent hepatic resection. The overall operative morbidity and mortality rates after hepatic resection were 41.7% and 16.7%, respectively. The median survival after hepatic resection was 16.4 months. The overall 1-, 3-, and 5-year survival rates after hepatic resection were 60.3%, 29.4% and 22.0%, respectively. Lymphatic permeation (P = 0.007) and hilar nodal metastases (P = 0.009) were found to be significantly associated with poor survival after hepatic resection. Hepatic resection is the treatment of choice for intrahepatic cholangiocarcinoma when it is resectable.